These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34445816)

  • 1. [Comparison of EB virus infection between short term and long term use of mycophenolate mofetil for prophylaxis of graft versus host disease after haploidentical hematopoietic stem cell transplantation].
    Yu CZ; Huang XJ; Xu LP; Liu KY; Zhang XH; Sun YQ; Liu JY; Zhao XY; Wang Y
    Zhonghua Nei Ke Za Zhi; 2021 Sep; 60(9):806-811. PubMed ID: 34445816
    [No Abstract]   [Full Text] [Related]  

  • 2. [Impact of mycophenolate mofetil prophylaxis duration on acute graft-versus-host disease after haploidentical stem cell transplantation].
    Sun YQ; Huang XJ; Xu LP; Zhang XH; Yan CH; Liu KY; Wang Y
    Zhonghua Xue Ye Xue Za Zhi; 2018 Apr; 39(4):286-291. PubMed ID: 29779322
    [No Abstract]   [Full Text] [Related]  

  • 3. Triple-Drug Graft-versus-Host Disease Prophylaxis after HLA-Matched Unrelated Donor Nonmyeloablative Allogenic Hematopoietic Stem Cell Transplantation.
    Wegener A; Andersen NS; Friis LS; Petersen SL; Schjødt I; Kornblit B; Sengeløv H; Gjærde LK
    Transplant Cell Ther; 2023 Sep; 29(9):575.e1-575.e6. PubMed ID: 37301257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delay expression of NKp30 on NK cells correlates with long-term mycophenolate mofetil treatment and higher EBV viremia post allogenic hematological stem cells transplantation.
    Yu XX; Cao XH; Yan H; Luo XY; Zhao XS; Sun YQ; Wang Y; Xu LP; Zhang XH; Chang YJ; Huang XJ; Zhao XY
    Clin Immunol; 2019 Aug; 205():49-56. PubMed ID: 31112757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of ATG-thymoglobulin with ATG-Fresenius for Epstein-Barr virus infections and graft-versus-host-disease in patients with hematological malignances after haploidentical hematopoietic stem cell transplantation: a single-center experience.
    Zhou L; Gao ZY; Lu DP
    Ann Hematol; 2020 Jun; 99(6):1389-1400. PubMed ID: 32291495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant Cyclophosphamide.
    Elmariah H; Otoukesh S; Kumar A; Haris Ali ; Shukaib Arslan ; Dimaggio E; Gonzalez R; Shouse G; Pourhassan H; Taiga Nishihori ; Faramand R; Mishra A; Khimani F; Fernandez H; Lazaryan A; Nieder M; Perez L; Liu H; Ryotaro Nakamura ; Pidala J; Guido Marcucci ; Stephen J Forman ; Anasetti C; Bejanyan N; Monzr M Al Malki
    Transplant Cell Ther; 2024 Oct; 30(10):1019.e1-1019.e9. PubMed ID: 39102983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation.
    Hamad N; Shanavas M; Michelis FV; Uhm J; Gupta V; Seftel M; Kuruvilla J; Lipton JH; Messner HA; Kim DD
    Am J Hematol; 2015 May; 90(5):392-9. PubMed ID: 25615933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal Active Anti-Thymocyte Globulin Exposure Associated with Minimum Risk of Virus Reactivation and Comparable Acute Graft-Versus-Host Disease Under Adult Myeloablative Haploidentical Peripheral Blood Stem Cell Transplantation.
    Wang H; Zhao Y; Fang S; Wang L; Peng B; Yang J; Wang N; Du J; Li F; Jin X; Luan S; Wu X; Dou L; Liu D
    Transplant Cell Ther; 2022 Jun; 28(6):332.e1-332.e10. PubMed ID: 35314377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
    Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
    Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
    Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of ruxolitinib in Graft-versus-Host disease prophylaxis for pediatric β-Thalassemia major patients after allogeneic stem cell transplantation: A retrospective cohort study.
    Hong X; Chen Y; Lu J; Lu Q
    Pediatr Transplant; 2023 Mar; 27(2):e14466. PubMed ID: 36597217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies.
    Baker M; Wang H; Rowley SD; Cai L; Pecora AL; Skarbnik A; Vesole DH; Adler-Brecher B; Kim D; Donato ML
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):2047-2055. PubMed ID: 27522040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation.
    Mehta RS; Saliba RM; Chen J; Rondon G; Hammerstrom AE; Alousi A; Qazilbash M; Bashir Q; Ahmed S; Popat U; Hosing C; Khouri I; Shpall EJ; Champlin RE; Ciurea SO
    Br J Haematol; 2016 May; 173(3):444-55. PubMed ID: 26947769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human herpesvirus 6 encephalitis in patients administered mycophenolate mofetil as prophylaxis for graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Inui Y; Yakushijin K; Okamura A; Tanaka Y; Shinzato I; Nomura T; Ichikawa H; Mizutani Y; Kitao A; Kurata K; Kakiuchi S; Miyata Y; Sanada Y; Kitagawa K; Uryu K; Kawamoto S; Yamamoto K; Matsuoka H; Murayama T; Ito M; Minami H
    Transpl Infect Dis; 2019 Feb; 21(1):e13024. PubMed ID: 30414316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A clinical study of haploidentical transplantation using granulocyte colony-stimulating factor stimulating donor bone marrow].
    Chen H; Ji S; Wang H
    Zhonghua Nei Ke Za Zhi; 2001 Nov; 40(11):760-3. PubMed ID: 11930684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients.
    Windreich RM; Goyal RK; Joshi R; Kenkre TS; Howrie D; Venkataramanan R
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):682-689. PubMed ID: 26740371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
    Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
    Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term Outcomes with Nonmyeloablative HLA-Identical Related Hematopoietic Cell Transplantation Using Tacrolimus and Mycophenolate Mofetil for Graft-versus-Host Disease Prophylaxis.
    Ueda Oshima M; Storer BE; Qiu H; Chauncey T; Asch J; Boyer MW; Giaccone L; Flowers M; Mielcarek M; Storb R; Maloney DG; Sandmaier BM
    Transplant Cell Ther; 2021 Feb; 27(2):163.e1-163.e7. PubMed ID: 33830025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil administered every 8 hours in combination with tacrolimus is efficacious in the prophylaxis of acute graft versus host disease in childhood, adolescent, and young adult allogeneic stem cell transplantation recipients.
    Militano O; Ozkaynak MF; Mehta B; van deVen C; Hamby C; Cairo MS
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27091. PubMed ID: 29667720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.